You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page.
Turn on more accessible mode
Turn off more accessible mode
Skip Ribbon Commands
Skip to main content
Turn off Animations
Turn on Animations
CTDetailNew
It looks like your browser does not have JavaScript enabled. Please turn on JavaScript and try again.
Appointment
Find a Condition or Treatment
Find a Doctor
Menu
MAIN
Back to Home
About Us
Corporate Profile
Newsroom
Visitors Information
Contact Us
Patient Care
Specialties & Services
Your Clinic Visit
Cancer Information & Patient Support
E-Services
Find a Doctor
Research & Innovation
Research Labs
Programmes
Facilities
Our Researchers
Clinical Trials
SingHealth Research
Education & Training
Overview
Division of Cancer Education
Events
SingHealth Academy
Careers
Sponsorship
Scholarships
Giving
Why Give
Get Involved
Your Gift at Work
Be Informed
Make a Gift
Our Campaign
Volunteer
Specialties & Services
Back to Home
Goh Cheng Liang Proton Therapy Centre
Haematology
Medical Oncology
Surgery & Surgical Oncology, SGH and NCCS
Radiation Oncology
Oncologic Imaging
Supportive & Palliative Care
Comprehensive Liver Cancer Clinic
Cancer Genetics Service
Lung Multidisciplinary Clinic
Nursing
NCCS Oncology @ SKH
NCCS Oncology Clinic @ CGH
Department of Psychosocial Oncology
Cancer Education and Information
Your Clinic Visit
Back to Home
Book an Appointment
When seeing a doctor
Pharmacy
Outpatient Pharmacy
Oncology Pharmacy
Search a medication
FAQ
Medicine
Charges & Payment
Financial Aid
Video Consultation
Rights & Responsibilities as a Patient
Cancer Information & Patient Support
Back to Home
For Patients
For Caregivers
Publications
Cancer Information Booklets
In Good Health
Inspirational Patient & Caregiver Awards
Patient Stories
E-Services
Back to Home
Make/Change/Cancel Appointment
Request for Medical Report
Health Buddy App
Find a Doctor
Home
to skip to the main content on a page
to skip to the main content on a page
About Us
Back to Home
Corporate Profile
Vision & Mission
NCCS Leadership
Annual Report
Awards
Key Milestones
Whistle-blowing Policy
Newsroom
Press Releases
Check Fake News
Visitors Information
Contact Us
Feedback Form
Patient Liaison Service
Patient Care
Back to Home
Specialties & Services
Goh Cheng Liang Proton Therapy Centre
Haematology
Medical Oncology
Surgery & Surgical Oncology, SGH and NCCS
Radiation Oncology
Oncologic Imaging
Supportive & Palliative Care
Comprehensive Liver Cancer Clinic
Cancer Genetics Service
Lung Multidisciplinary Clinic
Nursing
NCCS Oncology @ SKH
NCCS Oncology Clinic @ CGH
Department of Psychosocial Oncology
Cancer Education and Information
Your Clinic Visit
Book an Appointment
When seeing a doctor
Pharmacy
Medicine
Charges & Payment
Financial Aid
Video Consultation
Rights & Responsibilities as a Patient
Cancer Information & Patient Support
For Patients
For Caregivers
Publications
Patient Stories
E-Services
Make/Change/Cancel Appointment
Request for Medical Report
Health Buddy App
Find a Doctor
Research & Innovation
Back to Home
Research Labs
Cellular & Molecular Research
Medical Sciences
Clinical Trials & Epidemiological Sciences
NCCS Research Committee & Scientific Advisory Board
Research Divisions Organisation Chart
Programmes
Cancer Discovery Hub
STR-NCCS Satellite Tissue Bank
Joint Breast Cancer Registry
Data and Computational Science
Asia-Pacific Hepatocellular Carcinoma Trials Group
The VICTORY Consortium
ANCHOR
Facilities
Overview
Specialised Units
Shared Facilities
Shared Services
Research Contracts and Commercialisation
Our Researchers
Division of Medical Oncology
Division of Surgery & Surgical Oncology, SGH and NCCS
Division of Radiation Oncology
Division of Oncologic Imaging
Division of Supportive and Palliative Care
Cellular and Molecular Research
Division of Medical Sciences
Clinical Trials & Epidemiological Sciences
Research Reports
Clinical Trials
About Clinical Trials
Current Clinical Trials
ECRU
About Clinical Trials & Epidemiological Sciences
Clinical Trials Office
Biostatistics and Epidemiology Unit
SingHealth Research
Education & Training
Back to Home
Overview
Division of Cancer Education
Undergraduate Education Unit
Postgraduate Education Unit
Nursing Education Unit
Faculty Development & Support Education Unit
Primary Care Oncology Education Unit
Communications, Mentoring, Ethics and Professionalism Education Unit
Medical Humanities Education Unit
Events
SingHealth Academy
Careers
Back to Home
Sponsorship
Career Conversion Programme
Scholarships
Giving
Back to Home
Why Give
About Us
Funding Innovative Research
Preventing Cancer
Advancing Medical Education
Helping Our Patients
Furthering Donor Impact
How Your Gift Helps
Get Involved
Honouring Your Gift
Become a Corporate Donor
Leave Your Legacy
Fundraise for Us
Join a Special Event
Your Gift at Work
Stories of Hope
Researchers in Action
Support for Patients
Our Work in the Community
Training Future Experts
Be Informed
Our Publications
Financial Statements
Make a Gift
Our Campaign
Make More Survivors
Jeans For Genes
Women VS Cancer
BCAM 2024
LCAM 2023
Volunteer
Home
>
Patient Care
>
Conditions and Treatment
>
Acute Coronary Syndromes
>
Treatment
Facebook
WhatsApp
Email Us
share
Font Resize
A-
A
A+
Print
Acute Coronary Syndromes
Acute Coronary Syndromes - Symptoms
Acute Coronary Syndromes - Causes and Risk Factors
Acute Coronary Syndromes - Treatments
The goal of treatment for patients with ACS is to reduce or prevent further thrombus formation at the site of plaque rupture and relief of ischaemia by reducing the demand of heart muscle or increase the blood supply by unblocking the artery blockage.
Unstable angina and NSTEMI
The presentation and prognosis of unstable angina and NSTEMI are similar and therefore the treatment for both is the same. The only difference is that in NSTEMI, there is damage of a portion of heart muscle with abnormal increased levels of cardiac markers detected in the blood.
Reducing and preventing formation of thrombus
After the plaque ruptured in the artery, platelet plays a vital role in initiating the clot. If there is no contraindication, you will be given 2 types of antiplatelet agents to prevent further platelet deposition at the ruptured plaque. These 2 agents are also required when there is intention to perform coronary stenting (see below). Anti-coagulation (heparins) will also be given to dissolve the clot that has formed on the ruptured plaque. This is usually given as injection under the skin (subcutaneously) or occasionally as an infusion into a vein (intravenously). Please see Table 1 for various combinations of antiplatelet agents and anti-coagulation. Both antiplatelet and anticoagulation agents have been proven to reduce heart attack and death in patients with ACS.
Reducing demand and improving supply
At the beginning of your admission, you may be required to continuously rest in bed to reduce the demand of your heart until your condition become more stable. Oxygen will be given to improve oxygenation of the blood, thus increasing the oxygen supply to the heart. Medications like beta-blockers will be prescribed to slow down the heart rate, which reduces the demand of the heart muscle, while nitrates (IV or oral) dilate the artery to improve the blood supply to the heart muscle.
The most effective method to improve blood supply, however, is to unblock the artery, which can be done by either coronary angioplasty (inserting stents via the wrist or groin) or CABG, especially in patients with extensive or high risk blockages. (Figure 4 – TIMI risk score) In high risk patients, a coronary angiography is suggested to be performed within 24 hours to check the number and severity of the blocked coronary artery. Your doctor who performs the coronary angiography will advise you what the best treatment option is. In general, coronary stenting can be performed safely in patients with 1 or 2 blocked arteries but in patients with all 3 blocked arteries (especially patients with diabetes mellitus) CABG may be a better option.
STEMI
The treatment of STEMI is completely different from unstable angina and NSTEMI, in terms of urgency and treatment options. In STEMI, the artery is completely occluded by thrombus and the heart muscle supplied by that artery will be irreversibly damaged if not opened within 6 to 12 hours. The longer the artery remains occluded the more extensive the damage to the heart muscle and the speed of treatment in STEMI is therefore crucial.
There are 2 treatment options for STEMI – powerful clot buster (thrombolysis) or coronary stenting (primary angioplasty). Although intravenous thrombolysis is easy and fast, the success rate of opening the artery in STEMI is only 50 to 60%. It also carries the inherent risk of bleeding complications, especially intracranial haemorrhage, which is usually fatal. In NHCS, all patients with STEMI are considered for primary angioplasty if there is no contraindicated. The occluded artery is usually opened successfully in 90% of patients by inserting a stent at the site of ruptured plaque. Primary angioplasty in large centers and experienced operators has been shown to improve outcomes compared to intravenous thrombolysis. However, primary angioplasty for patients with STEMI needs to be performed immediately, preferably within 60 to 90 minutes of admission to ED, in order to achieve maximum benefit.
While in ED, patient will be given loading doses of 2 antiplatelet agents. Once the informed consent for primary angioplasty is given, the patient is transferred to cardiac catherisation laboratory where the primary angioplasty team members will immediately perform coronary angiography and stenting if appropriate. Occasionally stenting may not be required or possible and in some cases urgent coronary artery bypass surgery is necessary.
After the procedure (usually 60 to 90 minutes depending on the complexity of the lesions) the patient will be admitted to coronary care unit (CCU) for monitoring of heart rhythm and blood pressure. Patients with STEMI may develop life threatening rhythm and complications after heart attack. Early detection and treatment of these complications saves lives.
Similar to unstable angina and NSTEMI, medications to decrease the demand of heart muscle (beta-blocker) and improve blood supply to heart muscle (nitrates) will be given.
Acute Coronary Syndromes - Preparing for surgery
Acute Coronary Syndromes - Post-surgery care
Display Entire Article +
Diagnosis
Other Information
Tags:
Coronary Artery Disease / Coronary Heart Disease
Article contributed by
Department of Cardiology
,
National Heart Centre Singapore
The information provided is not intended as medical advice.
Terms of use
. Information provided by
Our Breast Team
Filter:
By designation or sub-specialty
By Designation:
By Sub-Specialty:
TOP
[]
Related Conditions
Coronary Artery Disease / Coronary Heart Disease
View more
Related Medicine
Healthy Living Tips
by
View more
Discover articles,videos, and guides afrom Singhealth's resources across the web. These information are collated, making healthy living much easier for everyone.
Understanding Chest Pain
Super Foods Good for Your Heart
Exercises for Cardiac Patients (Sitting)
Exercises for Cardiac Patients (Standing)
×
SUBSCRIBE VIA EMAIL
Subscribe to our mailing list to get the updates to your email inbox...
Find a Doctor
Condition & Treatment
Home
Appointment
E-services